Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 570 record(s)

Req # A-2023-000454

Adverse Drug Reaction (ADR) for GAMMAGARD LIQUID. Report number: 001035875. ADRs for IMMUNOGLOBULIN (HUMAN). Report numbers: E2B_06284236, E2B_06269470, E2B_06322702, E2B_06302546, 001038072, 001035863, 001038090. ADR for ANTIHEMOPHILIC FACTOR (HUMAN). Report number: E2B_06280036.

Organization: Health Canada

99 page(s)
October 2023

Req # A-2023-000467

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 23-103433-815.

Organization: Health Canada

36 page(s)
October 2023

Req # A-2023-000527

Adverse Drug Reactions (ADRs) for TAVNEOS. Report numbers: E2B_06365471, E2B_06378386, E2B_06398851. ADRs for ABILIFY MAINTENA. Report numbers: 001040048, 001042901, E2B_06373433, E2B_06388909.

Organization: Health Canada

90 page(s)
October 2023

Req # A-2023-000528

Adverse Drug Reactions (ADRs) for ARIPIPRAZOLE. Report numbers: E2B_06336965, E2B_06354662, E2B_06356700, E2B_06375857, E2B_06399745, E2B_06402151, E2B_06404345.

Organization: Health Canada

131 page(s)
October 2023

Req # A-2023-000535

Adverse Drug Reaction (ADR). Report number: E2B_05328556.

Organization: Health Canada

10 page(s)
October 2023

Req # A-2023-000614

Adverse Drug Reactions (ADRs). Report numbers: E2B_06318317, E2B_06318856, E2B_06331187.

Organization: Health Canada

28 page(s)
October 2023

Req # A-2023-000624

Adverse Drug Reactions (ADRs). Report numbers: 001041731, E2B_06032298, E2B_04916103, E2B_06343353.

Organization: Health Canada

51 page(s)
October 2023

Req # A-2023-000625

Adverse Drug Reaction (ADR). Report number: 001042222.

Organization: Health Canada

8 page(s)
October 2023

Req # A-2023-000629

Adverse Drug Reactions (ADRs) for IXAZOMIB. Report numbers: E2B_06369267, E2B_06363702. ADRs for PANTOLOC. Report numbers: 001041274, 001042681, 001043580. ADRs for PANTOPRAZOLE SODIUM. Report numbers: E2B_06337172, E2B_06386931, E2B_06374715, E2B_06401817. ADR for TECTA. Report number: 001047798.

Organization: Health Canada

334 page(s)
October 2023

Req # A-2023-000648

Adverse Drug Reactions (ADRs). Report numbers: 001034936, 001024752, E2B_06137209, E2B_06200914, E2B_06137218, E2B_05970491, E2B_06137660, E2B_06137610, E2B_02077692, E2B_02840835.

Organization: Health Canada

415 page(s)
October 2023
Date modified: